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Seventy-six patients with ventricular tachyarrhythmias
(40 sustained and 36 nonsustained) were treated with
oral flecainide. Radionuclide left ventricular ejection
fraction was 30% or less in 33 patients and greater than
30% in 43 patients. Before flecainide, compensated heart
failure was present in 23 patients (ejection fraction :S
30% in 15 and> 30% in 8). Flecainide mean dose was
150 mg twice daily and mean plasma concentration was
720 ng/ml. New or worsened congestive heart failure
occurred in seven patients on flecainide therapy, all with
an ejection fraction of hiss than 30%; six had a previous
history of compensated heart failure and of these, three
died. Ejection fraction was the only independent variable
Flecainide acetate is a benzamide compound with antiar-
rhythmic action. Clinical studies have demonstrated its elec-
trophysiologic properties (1-3) and efficacy in supressing
ventricular arrhythmias (4-8) and it has been placed in class
IC of the Vaughn-Williams antiarrhythmic drug classifica-
tion schema (9). In both experimental animals (10) and man
(II), flecainide has been reported to exert myocardial de-
pressant action, but the importance of this finding for the
clinical use of ftecainide has not been clearly defined. This
study was undertaken to investigate the influence of left
ventricular dysfunction on the results of flecainide therapy
in patients with refractory ventricular arrhythmias.
Methods
Study patients. The study population included 76 con-
secutive patients with ventricular tachycardia refractory to
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that significantly influenced efficacyand tolerance of fle-
cainide. After 1 year of therapy, efficacy and tolerance
was 58% (25 of 43) in patients with an ejection fraction
greater than 30% and 12% (4 of 33) in patients with an
ejection fraction of 30% or less (p < 0.001).
Thus, congestive heart failure can occur during fle-
cainide therapy, particularly in patients with a previous
history of congestive heart failure and ejection fraction
of less than 30%, and may particularly limit therapy in
these patients. Clinical efficacy and tolerance were sig-
nificantly lower in patients with an ejection fraction of
less than 30% .
(J Am Coll CardioI1987;9:163-8)
conventional antiarrhythmic agents used in therapeutic doses.
Forty patients had sustained and 36 had nonsustained ven-
tricular tachycardia. There were 65 men and II women,
with ages ranging from 30 to 78 years (mean 62 ± 9).
Coronary artery disease was present in 52 (68%) patients
and 36 had suffered a myocardial infarction more than 3
months before enrollment in this study. The underlying heart
disease in the remaining patients was idiopathic congestive
or hypertrophic cardiomyopathy (19 patients) and valvular
heart disease (3 patients). Two patients had no identifiable
organic heart disease. Twenty-three patients had a history
of congestive heart failure; of these II were in New York
Heart Association (NYHA) class II and 12 were in class III
or IV. Each patient was in a compensated state before ini-
tiation of flecainide therapy.
Definitions. Ventricular tachycardia was defined as the
presence of three or more sequential ventricular complexes
at a rate of greater than 100/min. If this arrhythmia was
longer than 30 seconds in duration or resulted in cardio-
vascular collapse, it was defined as sustained.
Efficacy was defined by either noninvasive or invasive
techniques. Patients with nonsustained ventricular tachy-
cardia were evaluated with noninvasive techniques (Holter
monitoring) and efficacy was defined as suppression of 100%
of ventricular tachycardia episodes, and greater than 75%
reduction of the frequency of ventricular premature com-
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plexes. In patients with sustained ventricular tachycardia,
efficacy was defined in the electrophysiologic laboratory as
prevention of initiation of sustained ventricular tachycardia
(::; 15 complexes) in patients in whom sustained ventricular
tachycardia had been inducible at baseline while they were
receiving no antiarrhythmic therapy. Flecainide was con-
sidered beneficial but not effective in electrophysiologic
testing if it produced more than a lOOms increase in the
cycle length of ventricular tachycardia and elimination of
severe symptoms, even though it failed to prevent initiation
of sustained ventricular tachycardia. Our clinical experience
has shown that these criteria identify a regimen that reduces
the severity of recurrences if they should occur. Patients
with efficacy or beneficial results were discharged on drug
therapy.
Clinical efficacy and tolerance were defined after I year
of therapy as absence of either arrhythmic death, arrhythmia
recurrence or severe toxicity requiring drug discontinuation.
"Congestive heart failure" was defined by the presence
(in the past or during drug therapy) of clear clinical evidence
of symptoms and signs of cardiac failure (for example,
shortness of breath on exertion or at rest, evidence of fluid
retention such as peripheral edema, pulmonary congestion
or jugular venous distension) which required treatment with
diuretics and inotropic or vasodilator drugs, or both, for
symptomatic relief. The functional classification system of
the NYHA was used (12).
Treatment protocol. During initiation of therapy, each
patient was hospitalized and placed on continuous telemetric
electrocardiographic monitoring. All antiarrhythmic drugs
were discontinued for at least five drug half-lives and clinical
laboratory evaluation, 24 hour Holter electrocardiographic
monitoring and radionuclide angiography were performed
in each patient. After written informed consent was ob-
tained, flecainide was initiated at a dose of 100 mg orally
every 12 hours. The dose was increased in 50 mg increments
at 4 day intervals in-hospital to achieve efficacy. If either
suppression of ventricular tachycardia was not achieved with
a dose of 200 mg every 12 hours or serious adverse effects
occurred, flecainide was discontinued. Patients were seen
daily by one of the investigators and questioned about symp-
toms related to left ventricular function. Radionuclide an-
giography was repeated after steady-state had been achieved
on a flecainide dose which suppressed the ventricular tachy-
cardia, or of 200 mg every 12 hours. If flecainide was
terminated prematurely because of toxicity, radionuclide
angiography may not have been repeated.
Follow-up. Patients were seen in an arrhythmia research
clinic by one of the investigators 1 month after initiation of
flecainide and every 3 months thereafter. At each visit,
patients were questioned about adverse experiences and
congestive heart failure symptoms. They also underwent a
clinical and laboratory evaluation, including a 24 hour Hol-
ter monitor recording and measurement of random plasma
flecainide concentration.
Statistical analysis. The results are presented as mean
± 1 SD. Statistical comparisons were made using the Stu-
dent t test; contingency tables were evaluated by chi-square
analysis and significance was defined as probability (p) less
than 0.05 using a two-tailed analysis. Equality of efficacy
and tolerance curves (patients on drug therapy) were ana-
lyzed using the Mantel-Cox and Breslow statistics. Logistic
regression was used to select independent variables (age,
sex, previous history of congestive heart failure, ejection
fraction, sustained or nonsustained ventricular arrhythmia
and flecainide dosage and plasma levels), that could influ-
ence efficacy and tolerance of flecainide.
Results
Baseline ejection fraction. The baseline radionuclide
ejection fraction was 33 ± 13%. Thirty-three patients had
an ejection fraction of 30% or less and 43 had an ejection
fraction greater than 30%. Of the 36 patients with nonsus-
tained ventricular tachycardia, 13 had an ejection fraction
of less than 30% and 23 of more than 30%. Of 40 patients
with sustained ventricular tachycardia, 20 had an ejection
fraction of less than 30% and 20 of more than 30%. Of the
23 patients who had a history of congestive heart failure
before initiation of flecainide therapy, 15 had an ejection
fraction of less than 30% and 8 of more than 30%.
Effect of f1ecainide on ejection fraction. Sixty-two of
the 76 patients were available for radionuclide ejection frac-
tion measurement on steady-state flecainide at the maxi-
mally tolerated dose or at a dose that controlled their ven-
tricular tachycardia. The mean ejection fraction of these
patients on flecainide was 32 ± 13% compared with 34 ±
13% at control (p > 0.05). Distinct individual changes in
ejection fraction (absolute variations> 5% between the pre-
and postdrug study) were seen in 22 patients. The ejection
fraction increased in 7 and decreased in 15 patients. At
baseline, 4 of these 22 patients had an ejection fraction
of less than 30% and 18 of greater than 30% (p > 0.05)
(Fig. 1).
Effect of f1ecainide on patients with congestive heart
failure. No patient with an ejection fraction greater than
30% developed worsening or new onset of congestive heart
failure after the initiation of flecainide therapy. Conversely
7 of 33 (21%) patients with an ejection fraction of 30% or
less had new onset or worsening of congestive heart failure
during f1ecainide therapy. Six of these patients had optimally
managed congestive heart failure before flecainide therapy
and one patient developed congestive heart failure for the
first time after drug administration (Fig. 2). Of 15 patients
with an ejection fraction of 30% or less and a history of
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Figure l. Effect of flecainide on ejection frac-
tion. Thebaseline(B)ejection fraction before fle-
cainide therapy and after achieving steady state
plasma concentrations at a dose that controlled
ventricular tachycardia or 200 mgevery 12hours
(for 7 days) are shown. The graph on the left
depicts data from all patients studied, the center
graph shows data from patients whose ejection
fraction increased and the graph on the right
from patients whose ejection fraction decreased.
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Table 1. Congestive Heart Failure During F1ecainide Therapy
*New York Heart Associati on functional classification for conge stive
heart failure (CHF). EF = ejection fraction.
o
o
o
o
o
o
Patients With an EF Over 30%
35
3
5
No. of CHF On
Previous Functional Class* Patients Flecainide Death
I 18 I 0
II 8 I 0
III/IV 7 5 3
I
II
III/IV
Flecainide discontinuation during in-hospital titra-
tion. Flecainide was discontinued in 31 of the 76 patients
during the short-term phase before hospital discharge. In
three patients, this discontinuation was caused by heart fail-
ure on drug therapy (two of these patients died with heart
failure within 24 hours after f1ecainide discontinuation) and
in one patient it was related to a lethal proarrhythmic effect
of the drug (incessant refractory ventricular tachycardia).
F1ecainide was discontinued in 19 patients because of in-
effectiveness. In 9 of these patients, lack of effectiveness
was documented by spontaneous recurrences of previously
documented ventricular tachycardia before hospital dis-
charge and in the remaining 10, lack of efficacy was doc-
umented by Holter monitoring (2 patients) or electrophys-
iologic studies (8 patients). In six patients, the discontinuation
was prompted by changes in the surface electrocardiogram
heart failure, f1ecainide produced worsening of heart failure
in 6 (40%).
Twelve patients had class III or IV congestive heart fail-
ure before initiation of f1ecainide therapy; seven patients had
an ejection fraction of 30% or less and five of greater than
30% (Table 1). On flecainide, five of these patients (all with
ejection fraction < 30%) had worsening of congestive heart
failure and three died. Two of these deaths were related to
severe heart failure and refractory ventricular tachycardia
during the in-hospital phase and one patient died suddenly
after hospital discharge. Worsening congestive heart failure
in this patient had been successfully managed with an al-
teration in the patient's heart failure regimen.
Figure 2. Distribution of patients (pt) accordingto ejection frac-
tion, previous history of heart failure andcongestiveheart failure
that developed while on flecainide therapy. The patients with a
previous historyof congestive heart fai lure are shown in thesingle
circles and those who developed new onset or worsening of
congestive heart failure in the double circle. The bottom row
indicates heart failure status during flecainide therapy. Only pa-
tients with an ejection fraction (EF) less than 30% developed
congestive heart failure on flecainide therapy.
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Figure 3. Life-table analysis of results in 45 patients (30 with
ejection fraction> 30% and 15 -s 30%) discharged on ftecainide
therapy. Efficacy and tolerance were significantly greater in pa-
tients with ejection fraction (EF) greater than 30% whencompared
with patients with ejection fraction less than 30%. The numbers
in parentheses indicate the number of patients who remained
available for analysis.
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Discussion
Ejection fraction during flecainide therapy. Flecain-
ide acetate is a potent suppressor of ventricular arrhythmias
in humans. Clinical and experimental observations have
demonstrated negative inotropic effects and a relatively low
incidence of new onset or worsening of congestive heart
failure. Previous studies (11) demonstrated that intravenous
flecainide in a dose of 1 or 2 mg/kg uniformly produced a
significant but mild decrease in left ventricular ejection frac-
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variable that significantly influenced efficacy and tolerance
(p < 0.001) (Fig. 4). Clinical efficacy and tolerance (pa-
tients on drug therapy) was 58% (25 of 43) in patients with
an ejection fraction of more than 30% and 12% (4 of 33)
in patients with an ejection fraction of less than 30% (p <
0.05). The clinical efficacy and tolerance was 26% (6 of
23) in patients who had congestive heart failure before fle-
cainide therapy and 43% (23 of 53) in patients who did not
(p > 0.05) (Fig. 5). The acute response in hospital was
greater in patients with nonsustained ventricular tachycardia
than in those with sustained ventricular tachycardia (72 ver-
sus 47%, p < 0.05). The chronic response to flecainide in
the two patient groups was not different (44 versus 32%,
p = NS) .
Figure 4. Clinical efficacy and tolerance (CET) of ftecainide as
a function of ejection fraction (EF). Patients were grouped by
ejection fraction on the abscissa. After I year, clinical efficacy
and tolerance were significantly greater in patients with ejection
fractiongreater than 30% when compared with patients with ejec-
tion fraction less than 30%.
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(four patients developed atrioventricular block, one sino-
atrial pauses and one junctional rhythm). Flecainide was
discontinued in two patients because of noncardiac side
effects.
Long-term response to fleeainide, After hospital dis-
charge, 45 patients were followed up on flecainide. Before
flecainide therapy, the ejection fraction was greater than
30% in 30 patients and 30% or less in 15; 13 had heart
failure and 32 did not. Within the first year, flecainide was
discontinued in 16 patients, in none because of heart failure.
Three patients had recurrence of sustained ventricular tachy-
cardia, five patients did not maintain suppression of ven-
tricular tachycardia as determined by Holter monitoring, two
patients developed atrioventricular (AV) block and two non-
cardiac side effects. Four patients died during follow-up
(three suddenly and one because of acute myocardial in-
farction).
After 1 year of therapy, the efficacy and tolerance in
these 45 patients discharged from the hospital was 83% (25
of 30) in patients with an ejection fraction greater than 30%
and 26% (4 of 15) in patients with an ejection fraction less
than 30% (p < 0.001) (Fig. 3). Six (43%) of 13 patients
with a history of congestive heart failure before flecainide
therapy and 23 (71%) of 32 without heart failure were still
on active therapy after 1 year (p > 0.05).
Overall clinical efficacy and tolerance of flecainide
related to ejection fraction and congestive heart failure
status before therapy. After 1 year of therapy, 29 (38%)
of the original 76 patients entered into this trial remained
on flecainide. Ejection fraction was the only independent
JACC Vol. 9. No. I
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Figure 5. Effect of ejection fraction (EF), previous history of
congestive heart failure (CHF) and type of ventricular tachycardia
on acute and chronic efficacy of flecainide therapy. On the ab-
scissa, are patients grouped by ejection fraction (EF > 30 and
EF :5 30%). history of heart failure and type of ventricular tachy-
cardia (nonsustained [NSVTl or sustained [SUVT]) . The solid
bars represent the acute (in-hospital ) efficacy and the hatched
bars represent the chronic (I year) efficacy. The number in each
group. and the number and percent ineach groupachievingclinical
efficacy and tolerance (CET) are indicated .
tion. Our patient group did not show a significant decrease
in left ventricularejection fraction . This difference is prob-
ably due to the time of evaluationand the low initial ejection
fraction of our patients. In addition, we were unable to
measure ejection fraction in those patients who developed
severe congestiveheart failureduring ftecainide therapyand
thus the potentially largestdecreases inejection fraction may
have been missed.
Congestive heart failure during tlecainide therapy. In
the present study, new onset of congestive heart failure or
worsening of previously stable congestive heart failure oc-
curred in 7 of 76 patients. The incidence of newor worsened
heart failure after institution of flecainide therapy was greater
than that reported (11) in a larger series of patientsreceiving
ftecainide primarilyfor suppression of ventricularpremature
complexes.This difference is undoubtedly due to our patient
population , which had a high incidence of left ventricular
dysfunction, previoushistoryof congestive heart failureand
serious ventricular arrhythmia. In the present study, we
found that the potential for worsening congestive heart fail-
ure was most notable in patients with an ejection fraction
less than 30% and severe congestive heart failure. Because
40% of patientswith an ejection fraction of 30% or less and
a historyof heart failure developedworseningof congestive
heart failure, extreme caution should be exercised in using
flecainide in this group of patients.
Comparison with other antiarrhythmic drugs. Little
emphasis was placed on the potential for antiarrhythmic
drugs to worsen or produce congestive heart failure before
the introduction of disopyramide (13). This latter agent was
the first antiarrhythmic drug that was reported to produce a
high incidence of new or worsened congestive heart failure.
In fact, it was reported to adversely effect left ventricular
function in as many as 50% of patients with a previous
history of heart failure. Podrid et al. (13) reported that
disopyramide produced congestive heart failure in 16% of
patients treated with the agent. In their series. congestive
heart failure generally remitted when the drug was discon-
tinued. In our series of high risk patients, ftecainide produced
worseningof congestiveheart failure in a smallerpercentage
of patients, although in some the deterioration of left ven-
tricular function was life-threatening.
Role of ejection fraction in clinical efficacy of flecain-
ide. One of the most important predictors of outcome in
patients with cardiac disease is left ventricular function
(14-19). The risk of sudden death is greatest in patients
with reduced left ventricular function, and a low left ven-
tricularejection fraction is a sensitive indicatorof both early
and late mortality after myocardial infarction (20) . Recent
electrophysiologic studies have also suggested that the
suppression of inducible ventricular tachyarrhythmias by
manyconventional and investigational antiarrhythmic drugs
is signifi cantly affected by the left ventricularejection frac-
tion (21 -23) . Therefore, it is not surprising that the clinical
efficacy of ftecainide noted in the present study was sig-
nificantly lower in patients with a reduced ejection fraction.
The most important challenge for antiarrhythmic drugs
is to prevent sudden death in a well defined high risk group
of patientswith ventriculararrhythmiasand severe left ven-
tricular dysfunction. The efficacy and tolerance of all anti-
arrhythmic drugs will probably be lower in these patients.
Also, this stratification will be useful in comparing theeffect
of antiarrhythmic drugs with the clinical outcome.
Clinical implications. Flecainide is an antiarrhythmic
drug that can be used in patients with ventriculartachycardia
after careful in-hospital dose titration. Such patients with a
left ventricular ejection fraction of 30% or less and a pre-
vious history of congestive heart failure are, however, at
major risk for developing serious cardiac adverse effects
from antiarrhythmic drugs. Because it is infrequently ef-
fective and has considerable toxicity in patients with an
ejection fraction less than 30% and congestiveheart failure,
flecainide should not generally be used in this group. If
flecainide is selected for therapy in this group, it should be
initiated in-hospital with particular attention paid to devel-
opment of a new or worsened congestive heart failure, at
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which time the drug should be discontinued or the dose
adjusted .
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